CXCR2/CD182/IL8RB recombinant proteins and antibodies

C-X-C Chemokine Receptor Type 2 (CXCR2), also known as CD182 or IL8RB, is a chemokine receptor that primarily regulates immune responses through neutrophils and plays a significant role in various inflammatory and immune responses. CXCR2 interacts with its ligands, including CXCL1, CXCL2, and CXCL3, to activate downstream signaling pathways, attracting immune cells such as neutrophils and monocytes to sites of inflammation. This function is crucial for anti-infection responses and immune surveillance. The abnormal activation of CXCR2 is associated with several diseases, particularly in tumor immune evasion, chronic inflammation, and autoimmune disorders.

Studies have shown that increased expression of CXCR2 in the tumor microenvironment can promote tumor growth and metastasis. CXCR2 helps recruit immune-suppressive cells, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), to the tumor site, inhibiting anti-tumor immune responses and allowing tumors to escape immune surveillance. Additionally, CXCR2 plays an important role in chronic inflammation, respiratory diseases (e.g., chronic obstructive pulmonary disease and asthma), and some autoimmune diseases.

Due to CXCR2’s crucial role in various diseases, drug development targeting CXCR2 is advancing rapidly. Current research focuses on the development of CXCR2 inhibitors, which can block the binding of CXCR2’s ligands, reducing the migration of neutrophils and alleviating inflammation, while also inhibiting tumor growth and metastasis. CXCR2 inhibitors have been applied in several preclinical studies, particularly for treating tumor immune evasion. As the understanding of CXCR2’s mechanism of action deepens, CXCR2-targeted drugs are expected to become an effective therapeutic weapon for treating a variety of diseases in the future.

To assist in the development of CXCR2 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for CXCR2 targets. Products include active CXCR2 recombinant proteins, full-length CXCR2 proteins, CXCR2 reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of CXCR2 biotherapy, DIMA BIOTECH has also prepared a CXCR2 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CXCR2 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.